DE69535178T2
(de)
*
|
1994-06-10 |
2006-12-14 |
Genvec, Inc. |
Adenoviren-vektor systeme und zelllinien
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
EA001616B1
(ru)
|
1995-02-28 |
2001-06-25 |
Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ |
Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
*
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
DK1445322T4
(da)
|
1995-06-15 |
2012-09-03 |
Crucell Holland Bv |
Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
ATE420182T1
(de)
*
|
1996-09-25 |
2009-01-15 |
Scripps Research Inst |
Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
|
JP2001509168A
(ja)
*
|
1997-01-29 |
2001-07-10 |
コーネル リサーチ ファウンデーション、インコーポレイティッド |
血管新生を誘導するためのアデノウイルスベクターの多部位送達
|
US6348450B1
(en)
*
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
US6328958B1
(en)
|
1998-08-28 |
2001-12-11 |
Duke University |
Deleted adenovirus vectors and methods of making and administering the same
|
US6303362B1
(en)
*
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
CA2371069A1
(en)
*
|
1999-04-23 |
2001-02-01 |
Crucell Holland B.V. |
Means and methods for nucleic acid transfer
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
US6793926B1
(en)
|
1999-05-27 |
2004-09-21 |
Genovo, Inc. |
Methods for production of a recombinant adeno-associated virus
|
US6627190B2
(en)
*
|
1999-07-12 |
2003-09-30 |
Saint Louis University |
Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
|
US6613516B1
(en)
*
|
1999-10-30 |
2003-09-02 |
Affymetrix, Inc. |
Preparation of nucleic acid samples
|
US6867022B1
(en)
|
2000-01-21 |
2005-03-15 |
Regents Of The University Of Michigan |
Replication deficient adenovirus vectors and methods of making and using them
|
US7653769B2
(en)
*
|
2006-12-14 |
2010-01-26 |
International Business Machines Corporation |
Management of devices connected to infiniband ports
|
US6821775B1
(en)
*
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
US6591543B2
(en)
*
|
2000-04-14 |
2003-07-15 |
Kenneth P. Sabine |
Top water lure with highly active propeller
|
AU5882801A
(en)
|
2000-05-26 |
2001-12-03 |
Sumitomo Pharmaceuticals Company, Limited |
Novel recombinant adenovirus vector with relieved side effects
|
US6579522B1
(en)
*
|
2000-06-27 |
2003-06-17 |
Genvec, Inc. |
Replication deficient adenoviral TNF vector
|
EP1203819A3
(en)
*
|
2000-10-06 |
2002-08-07 |
Transgene S.A. |
Anti-inflammatory vectors
|
US6573092B1
(en)
*
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
EP1427816A4
(en)
|
2001-09-18 |
2004-12-01 |
Clontech Lab Inc |
METHOD FOR PRODUCING ADENOVIRAL VECTORS BASED ON A SITE SPECIFIC RECOMBINASE
|
US20030087438A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
E1-revertant-free adenoviral composition
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
US20030158112A1
(en)
*
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
AU2003302216A1
(en)
*
|
2002-05-08 |
2004-06-23 |
Virxsys Corporation |
Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
|
AU2003285009B2
(en)
*
|
2002-10-23 |
2010-10-07 |
Virxsys Corporation |
Screening methods for identification of efficient pre-trans-splicing molecules
|
CA2507036A1
(en)
*
|
2002-12-02 |
2004-06-17 |
Genvec, Inc. |
Materials and methods for treating ocular-related disorders
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
JP2006520604A
(ja)
*
|
2003-03-19 |
2006-09-14 |
アイソジェニス・インコーポレイテッド |
CD8α鎖に基づき免疫原性が減少した遺伝子治療ベクター
|
EP1649028B1
(en)
*
|
2003-07-25 |
2012-08-22 |
Genvec, Inc. |
Adenoviral vector-based vaccines
|
JP2007511507A
(ja)
*
|
2003-11-14 |
2007-05-10 |
ジェンベク、インコーポレイティッド |
癌を処置するための治療レジメン
|
WO2005051971A1
(en)
*
|
2003-11-24 |
2005-06-09 |
Canji, Inc. |
Reduction of dermal scarring
|
CA2553828A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
WO2005070948A1
(en)
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
EP1780269B1
(en)
*
|
2004-02-23 |
2009-07-08 |
Crucell Holland B.V. |
Virus purification methods
|
JP2007528903A
(ja)
*
|
2004-03-12 |
2007-10-18 |
ジェンベク、インコーポレイティッド |
眼における血管漏出を処置するための物質
|
EP2567967A3
(en)
|
2004-04-12 |
2013-08-21 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Method of using adenoviral vectors to induce an immune response
|
CN101068574B
(zh)
*
|
2004-07-20 |
2012-07-18 |
伊索格尼斯股份有限公司 |
与自身抗原有关的自身免疫和疾病的特异性抑制
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
CA2589602A1
(en)
*
|
2004-09-01 |
2006-04-13 |
Genvec, Inc. |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
AU2005326784B2
(en)
*
|
2004-10-08 |
2012-03-15 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
US20060188481A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Saitama Medical School |
Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
|
AU2006216671A1
(en)
|
2005-02-23 |
2006-08-31 |
The Uab Research Foundation |
Alkyl-glycoside enhanced vaccination
|
AU2006233800B2
(en)
*
|
2005-04-11 |
2011-07-07 |
Crucell Holland B.V. |
Virus purification using ultrafiltration
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US8765146B2
(en)
*
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
EP1951297A2
(en)
*
|
2005-11-10 |
2008-08-06 |
GenVec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
US20080248060A1
(en)
*
|
2007-01-09 |
2008-10-09 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
ATE495239T1
(de)
*
|
2007-03-09 |
2011-01-15 |
Vectorlogics Inc |
Zellen für adenovirusvektor- und proteinherstellung
|
US20100263066A1
(en)
*
|
2007-04-30 |
2010-10-14 |
Medtronic, Inc |
Inert dna sequences for efficient viral packaging and methods of use
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
WO2010033722A2
(en)
|
2008-09-17 |
2010-03-25 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
BRPI0921651A2
(pt)
*
|
2008-11-03 |
2015-08-18 |
Crucell Holland Bv |
Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
|
CA2777116C
(en)
|
2009-10-15 |
2020-09-01 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
KR101749779B1
(ko)
|
2009-10-15 |
2017-06-21 |
크루셀 홀란드 비.브이. |
아데노바이러스 입자의 정제 방법
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
EP2853266B1
(en)
|
2009-11-09 |
2018-01-31 |
Genvec, Inc. |
Method of propagating monkey adenoviral vectors
|
CN102762721B
(zh)
|
2010-02-15 |
2015-03-11 |
克鲁塞尔荷兰公司 |
用于生产Ad26腺病毒载体的方法
|
ES2887335T3
(es)
|
2010-03-17 |
2021-12-22 |
Univ Cornell |
Vacuna contra las drogas de abuso basada en adenovirus alterado
|
WO2011119773A1
(en)
|
2010-03-23 |
2011-09-29 |
Roeth Jeremiah F |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
EP2618838A1
(en)
|
2010-09-20 |
2013-07-31 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
EP2681327B1
(en)
|
2011-03-04 |
2018-11-21 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
WO2013052811A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vectors and methods of use
|
CN103987726B
(zh)
|
2011-10-05 |
2017-10-03 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
CA2850629C
(en)
|
2011-10-05 |
2024-05-21 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
EP2764011B1
(en)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2809346A1
(en)
|
2012-02-02 |
2014-12-10 |
GenVec, Inc. |
Adenoviral vector-based malaria vaccine
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
SG11201405228VA
(en)
|
2012-03-12 |
2014-11-27 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
SG11201405803PA
(en)
|
2012-03-22 |
2014-11-27 |
Crucell Holland Bv |
Vaccine against rsv
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
WO2013181128A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Modified serotype 28 adenoviral vectors
|
RS58436B1
(sr)
|
2013-04-25 |
2019-04-30 |
Janssen Vaccines & Prevention Bv |
Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
|
KR102313153B1
(ko)
|
2013-06-17 |
2021-10-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 예비융합 rsv f 폴리펩타이드
|
EA036046B1
(ru)
|
2013-09-19 |
2020-09-18 |
Янссен Вэксинс Энд Превеншн Б.В. |
Композиция для стабилизации количества, эффективности, инфекционности и качества аденовирусов
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
TWI710635B
(zh)
*
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
PT3215187T
(pt)
|
2014-11-04 |
2018-11-27 |
Janssen Vaccines & Prevention Bv |
Vacinas terapêuticas contra hpv16
|
EP3236998A1
(en)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Recombinant metapneumovirus f proteins and their use
|
CN107406835A
(zh)
|
2015-01-20 |
2017-11-28 |
美利坚合众国,由健康及人类服务部部长代表 |
表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
LT3271729T
(lt)
|
2015-03-18 |
2021-02-25 |
Janssen Vaccines & Prevention B.V. |
Rekombinantinių raiškos sistemų analizės būdai
|
PL3283634T3
(pl)
|
2015-04-14 |
2019-10-31 |
Janssen Vaccines & Prevention Bv |
Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsv fポリペプチド
|
PL3319633T3
(pl)
|
2015-07-07 |
2021-04-19 |
Janssen Vaccines & Prevention B.V. |
Szczepionka przeciwko rsv
|
MY195389A
(en)
|
2015-08-20 |
2023-01-18 |
Janssen Vaccines & Prevention Bv |
Therapeutic HPV18 Vaccines
|
EP3359132B1
(en)
|
2015-10-06 |
2023-08-16 |
Janssen Vaccines & Prevention B.V. |
Methods for preventing plastic-induced degradation of biologicals
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
US10808011B2
(en)
|
2016-03-09 |
2020-10-20 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant HIV-1 envelope proteins and their use
|
LT3439672T
(lt)
|
2016-04-05 |
2021-01-25 |
Janssen Vaccines & Prevention B.V. |
Stabilizuotas tirpus rsv f baltymas prieš suliejimą, skirtas naudoti rsv infekcijos profilaktikai
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
WO2017192418A1
(en)
|
2016-05-02 |
2017-11-09 |
Janssen Vaccine & Prevention B.V. |
Therapeutic hpv vaccine combinations
|
MY194419A
(en)
|
2016-05-30 |
2022-11-30 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins
|
BR112018075969A2
(pt)
|
2016-06-20 |
2019-04-02 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
WO2018064523A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
EP3518968B1
(en)
|
2016-10-03 |
2022-01-05 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Hiv-1 env fusion peptide immunogens and their use
|
US10960070B2
(en)
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
CA3043790A1
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
EP3580340A1
(en)
|
2017-02-09 |
2019-12-18 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
EP3600405A1
(en)
|
2017-03-24 |
2020-02-05 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of hiv-1 gp120 and their use
|
US11229692B2
(en)
|
2017-05-17 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
KR20200053518A
(ko)
|
2017-09-15 |
2020-05-18 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 면역의 안전한 유도를 위한 방법
|
WO2019079337A1
(en)
|
2017-10-16 |
2019-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
|
MX2020004488A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
US11459583B2
(en)
|
2017-10-31 |
2022-10-04 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
KR20200083510A
(ko)
|
2017-10-31 |
2020-07-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
JP7285833B2
(ja)
|
2017-10-31 |
2023-06-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルス及びその用途
|
SI3743106T1
(sl)
|
2018-01-23 |
2022-10-28 |
Janssen Vaccines & Prevention B. V. |
Cepiva proti virusu influence in njihove uporabe
|
CA3092935A1
(en)
|
2018-03-06 |
2019-09-12 |
Precigen, Inc. |
Hepatitis b vaccines and uses of the same
|
US20210340188A1
(en)
|
2018-10-22 |
2021-11-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Recombinant gp120 protein with v1-loop deletion
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020263900A1
(en)
|
2019-04-25 |
2021-10-14 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
KR20220008816A
(ko)
|
2019-05-15 |
2022-01-21 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
|
SG11202113187WA
(en)
*
|
2019-05-30 |
2021-12-30 |
Gritstone Bio Inc |
Modified adenoviruses
|
EP4025247A1
(en)
|
2019-09-05 |
2022-07-13 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
KR20220076497A
(ko)
|
2019-10-03 |
2022-06-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 벡터 및 이의 용도
|
EP4041873A4
(en)
|
2019-10-08 |
2023-10-25 |
Trustees of Boston College |
PROTEINS CONTAINING MULTIPLE DIFFERENT NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING SUCH PROTEINS
|
BR112022009598A2
(pt)
|
2019-11-18 |
2022-08-16 |
Janssen Biotech Inc |
Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
|
CA3170322A1
(en)
|
2020-02-11 |
2021-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 vaccine
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
EP4135757A1
(en)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
CN116096407A
(zh)
|
2020-04-29 |
2023-05-09 |
美国政府(由卫生和人类服务部的部长所代表) |
重组人偏肺病毒f蛋白及其用途
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
EP4175721A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
WO2022232648A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
EP4380613A1
(en)
|
2021-08-03 |
2024-06-12 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|